25420-97-7

Basic information

• Product Name: Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside
• Synonyms: 2,3,4-Tri-O-triMethylsilyllincoMycin;Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside
• CAS NO: 25420-97-7
• Molecular Formula: C₂₇H₅₈N₂O₆SSi₃
• Molecular Weight: 623.08072
• Mol File: 25420-97-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 620.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 14.20±0.40(Predicted)
• CAS DataBase Reference: Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside(25420-97-7)
• EPA Substance Registry System: Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside(25420-97-7)

Safety Data

• Hazardous Substances Data: 25420-97-7(Hazardous Substances Data)

Usage

Description

Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-2,3,4-tris-O-(trimethylsilyl)-D-erythro-α-D-galacto-octopyranoside is a complex organic compound with a unique chemical structure. It is characterized by its multiple functional groups, including a methyl group, a carbonyl group, an amino group, and a thioether linkage. The compound also features a tris-O-(trimethylsilyl) group, which is significant for its stability and reactivity. Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside has potential applications in various fields due to its unique properties and reactivity.

Uses

1. Used in Pharmaceutical Industry:
Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-2,3,4-tris-O-(trimethylsilyl)-D-erythro-α-D-galacto-octopyranoside is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of new drugs with potential therapeutic applications.
2. Used in Chemical Research:
Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]aMino]-1-thio-2,3,4-tris-O-(triMethylsilyl)-D-erythro-α-D-galacto-octopyranoside is also used in chemical research as a model system for studying the reactivity and properties of complex organic molecules. Its unique structure allows researchers to explore various reaction pathways and mechanisms, contributing to the advancement of organic chemistry.
3. Used in Material Science:
Methyl 6,8-Dideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-2,3,4-tris-O-(trimethylsilyl)-D-erythro-α-D-galacto-octopyranoside may have potential applications in material science, particularly in the development of novel materials with specific properties. Its unique structure and functional groups could be exploited to create materials with tailored characteristics for various applications.
4. Used in Drug Delivery Systems:
Similar to gallotannin, this compound could be employed in the development of drug delivery systems to improve the bioavailability and therapeutic outcomes of various pharmaceutical agents. Its unique structure and reactivity may allow for the design of innovative drug carriers and delivery platforms.

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 154-21-2 lincomycin 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 859-18-7 lincomycin hydrochloride 

Downstream Products

• 1630970-40-9 C₅₀H₉₁N₅O₁₄SSi₃ 
• 1620159-41-2 C₄₁H₆₇N₅O₁₄S 
• 941588-19-8 7(S)-7-(4-aminophenylthio)-7-deoxylincomycin 
• 941587-68-4 7(S)-7-deoxy-7-(4-methoxycarbonylphenylthio)lincomycin 
• 941587-76-4 7(S)-7-deoxy-7-(3-methoxycarbonylphenylthio)lincomycin 
• 759397-47-2 7(S)-7-deoxy-7-phenylthiolincomycin 
• 941588-55-2 7(S)-7-deoxy-7-(2-nitrophenylthio)lincomycin 
• 941587-70-8 7(S)-7-deoxy-7-(3-nitrophenylthio)lincomycin 
• 941587-69-5 7(S)-7-deoxy-7-(4-nitrophenylthio)lincomycin 
• 941586-41-0 7(S)-7-deoxy-7-(5-(4-(difluoromethylthio)phenylamino)-1,3,4-thiadiazol-2-ylthio)lincomycin 
• 941586-07-8 (7S)-7-deoxy-7-(5-phenyl-1,3,4-thiadiazol-2-yl-thio)lincomycin 
• 941589-96-4 7(S)-7-deoxy-7-[1-(4-nitrophenyl)azetidin-3-ylthio]lincomycin 
• 941590-00-7 7(S)-7-[1-(4-aminophenyl)azetidin-3-ylthio]-7-deoxylincomycin 
• 941589-95-3 7(S)-7-deoxy-7-[1-(2-nitrophenyl)azetidin-3-ylthio]lincomycin 

Relevant articles and documents

Preparation method of clindamycin hydrochloride impurities

The invention relates to a preparation method of clindamycin hydrochloride impurities, which belongs to the field of medicines. The technical problem to be solved by the invention is that a method forefficiently preparing clindamycin hydrochloride impurities 7-epilincomycin and 7-epilincomycin hydrochloride reference substances is lacked in the prior art. The invention provides a preparation method of a clindamycin hydrochloride impurity intermediate shown as a formula II, which comprises the following steps: by using a compound shown as a formula I and R1COOH as raw materials, carrying out aMitsunobu substitution reaction for preparation, and adding amine and/or a nitrogen-containing aromatic heterocyclic compound into a reaction solution. The invention further provides a complete synthesis method of the 7-epilincomycin and the 7-epilincomycin hydrochloride. The complete synthesis method comprises the following steps: by taking lincomycin as a raw material, carrying out silicon protection group coating, selective deprotection, Mitsunobu substitution reaction and hydrolysis reaction to obtain the 7-epilincomycin, and further carrying out a chlorination reaction to prepare the 7-epilincomycin hydrochloride.

Synthesis and antibacterial activity of novel lincomycin derivatives. I. Enhancement of antibacterial activities by introduction of substituted azetidines

The synthesis and antibacterial activity of (7S)-7-sulfur-Azetidin-3-yl lincomycin derivatives are described. Modification was achieved by a simple reaction of (7R)-7-O-methanesulfonyllincomycin and the corresponding substituted azetidine-2-Thiol. Several

LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.